Compile Data Set for Download or QSAR
maximum 50k data
Report error Found 326 Enz. Inhib. hit(s) with all data for entry = 5329
TargetSerine/threonine-protein kinase receptor R3(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM143311(US10017516, Compound 11 | US9682983, 11)
Affinity DataIC50:  4nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetSerine/threonine-protein kinase receptor R3(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111123(US10017516, Compound 2 | US9682983, 2)
Affinity DataIC50:  4nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetSerine/threonine-protein kinase receptor R3(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111123(US10017516, Compound 2 | US9682983, 2)
Affinity DataIC50:  5.80nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetBone morphogenetic protein receptor type-1A(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111123(US10017516, Compound 2 | US9682983, 2)
Affinity DataIC50:  6.5nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM143311(US10017516, Compound 11 | US9682983, 11)
Affinity DataIC50:  7.70nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM161920(US10017516, Compound 53 | US9682983, 52 | US968298...)
Affinity DataIC50:  8nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111123(US10017516, Compound 2 | US9682983, 2)
Affinity DataIC50:  8.60nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetBone morphogenetic protein receptor type-1A(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111123(US10017516, Compound 2 | US9682983, 2)
Affinity DataIC50:  9.10nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetBone morphogenetic protein receptor type-1A(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM143311(US10017516, Compound 11 | US9682983, 11)
Affinity DataIC50:  9.20nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111123(US10017516, Compound 2 | US9682983, 2)
Affinity DataIC50:  10nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetSerine/threonine-protein kinase receptor R3(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM108945(US10017516, Compound 48 | US9682983, 48)
Affinity DataIC50:  11nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
In DepthDetails US Patent


TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM127883(US10017516, Compound 6 | US9682983, 6)
Affinity DataIC50:  12nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM161910(US10017516, Compound 42 | US9682983, 42)
Affinity DataIC50:  14nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM160069(US10017516, Compound 39 | US9682983, 39)
Affinity DataIC50:  15nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetBone morphogenetic protein receptor type-1B(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM148348(US10017516, Compound 22 | US9682983, 22)
Affinity DataIC50:  15nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM161914(US10017516, Compound 46 | US9682983, 46)
Affinity DataIC50:  16nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM118134(US10017516, Compound 3 | US9682983, 3)
Affinity DataIC50:  16nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetSerine/threonine-protein kinase receptor R3(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM143566(US10017516, Compound 13 | US9682983, 13)
Affinity DataIC50:  16nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetSerine/threonine-protein kinase receptor R3(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM148371(US10017516, Compound 32 | US9682983, 32)
Affinity DataIC50:  17nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM161912(US10017516, Compound 44 | US9682983, 44)
Affinity DataIC50:  17nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM143207(US10017516, Compound 7 | US9682983, 7)
Affinity DataIC50:  19nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetSerine/threonine-protein kinase receptor R3(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM143282(US10017516, Compound 10 | US9682983, 10)
Affinity DataIC50:  19nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetSerine/threonine-protein kinase receptor R3(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM143246(US10017516, Compound 8 | US9682983, 8)
Affinity DataIC50:  22nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM148372(US10017516, Compound 33 | US9682983, 33)
Affinity DataIC50:  22nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM160478(US10017516, Compound 41 | US9682983, 41)
Affinity DataIC50:  22nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetBone morphogenetic protein receptor type-1B(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM143311(US10017516, Compound 11 | US9682983, 11)
Affinity DataIC50:  22nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM143282(US10017516, Compound 10 | US9682983, 10)
Affinity DataIC50:  23nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetSerine/threonine-protein kinase receptor R3(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM127883(US10017516, Compound 6 | US9682983, 6)
Affinity DataIC50:  23nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM143566(US10017516, Compound 13 | US9682983, 13)
Affinity DataIC50:  23nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM148388(US10017516, Compound 37 | US9682983, 37)
Affinity DataIC50:  24nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM143246(US10017516, Compound 8 | US9682983, 8)
Affinity DataIC50:  24nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetSerine/threonine-protein kinase receptor R3(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM143207(US10017516, Compound 7 | US9682983, 7)
Affinity DataIC50:  25nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetActivin receptor type-1B(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM143311(US10017516, Compound 11 | US9682983, 11)
Affinity DataIC50:  25nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM148349(US10017516, Compound 23 | US9682983, 23)
Affinity DataIC50:  26nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetSerine/threonine-protein kinase receptor R3(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM118134(US10017516, Compound 3 | US9682983, 3)
Affinity DataIC50:  27nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM161925(US10017516, Compound 57 | US9682983, 57)
Affinity DataIC50:  28nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111122(US10017516, Compound 17 | US9682983, 1 | US9682983...)
Affinity DataIC50:  29nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetBone morphogenetic protein receptor type-1A(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM143566(US10017516, Compound 13 | US9682983, 13)
Affinity DataIC50:  29nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM148379(US10017516, Compound 35 | US9682983, 35)
Affinity DataIC50:  30nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetSerine/threonine-protein kinase receptor R3(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM161920(US10017516, Compound 53 | US9682983, 52 | US968298...)
Affinity DataIC50:  30nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM148357(US10017516, Compound 28 | US9682983, 28)
Affinity DataIC50:  31nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM160477(US10017516, Compound 40 | US9682983, 40)
Affinity DataIC50:  32nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM161922(US10017516, Compound 54 | US9682983, 54)
Affinity DataIC50:  32nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM161933(US10017516, Compound 65 | US9682983, 65)
Affinity DataIC50:  34nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetBone morphogenetic protein receptor type-1B(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM143282(US10017516, Compound 10 | US9682983, 10)
Affinity DataIC50:  38nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM148370(US10017516, Compound 31 | US9682983, 31)
Affinity DataIC50:  38nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111122(US10017516, Compound 17 | US9682983, 1 | US9682983...)
Affinity DataIC50:  40nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM161929(US10017516, Compound 61 | US9682983, 61)
Affinity DataIC50:  41nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetSerine/threonine-protein kinase receptor R3(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM160069(US10017516, Compound 39 | US9682983, 39)
Affinity DataIC50:  41nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM161927(US10017516, Compound 59 | US9682983, 59)
Affinity DataIC50:  43nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


Displayed 1 to 50 (of 326 total ) | Next | Last >>
Jump to: